Table 4.
Homozygote (TT vs. CC) | Heterozygote (CT vs. CC) | Dominant (TT+CT vs. CC) | Recessive (TT vs. CT+CC) | Allelic (T vs. C) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Groups | Cases/Controlsa |
ORb (95% CI) |
Pc | I2 |
ORb (95% CI) |
Pc | I2 |
ORb (95% CI) |
Pc | I2 |
ORb (95% CI) |
Pc | I2 |
ORb (95% CI) |
Pc | I2 |
All studies | 41,673/49,570 | 0.88 (0.79–0.98) | <1e−4 | 77.1 | 1.00 (0.93–1.08) | <1e−4 | 70.4 | 0.97 (0.89–1.05) | <1e−4 | 76.8 | 0.89 (0.83–0.96) | <1e−4 | 68.6 | 0.95 (0.90–1.00) | <1e−4 | 78.9 |
Controls in HWE d | 36,620/42,501 | 0.88 (0.80–0.98) | <1e−4 | 74.6 | 1.00 (0.93–1.08) | <1e−4 | 66.3 | 0.97 (0.89–1.04) | <1e−4 | 74.3 | 0.88 (0.82–0.95) | <1e−4 | 67.7 | 0.94 (0.89–0.99) | <1e−4 | 77.3 |
QUALITY | ||||||||||||||||
High (>8) | 38,503/46,453 | 0.87 (0.77–0.97) | <1e−4 | 78.1 | 0.98 (0.91–1.06) | <1e−4 | 69.6 | 0.94 (0.87–1.03) | <1e−4 | 76.7 | 0.88 (0.81–0.95) | <1e−4 | 70.9 | 0.93 (0.88–0.99) | <1e−4 | 79.7 |
Low (≤8) | 3170/3117 | 098 (0.70–1.38) | <1e−4 | 68.3 | 1.09 (0.80–1.48) | <1e−4 | 71.9 | 1.07 (0.80–1.44) | <1e−4 | 74 | 0.97 (0.79–1.18) | 0.025 | 44.5 | 1.03 (0.87–1.22) | <1e−4 | 71 |
GENOTYPING | ||||||||||||||||
PCR–RFLP | 15,282/18,081 | 0.85 (0.69–1.04) | <1e−4 | 81.4 | 0.96 (0.83–1.11) | <1e−4 | 77.8 | 0.93 (0.80–1.09) | <1e−4 | 82.9 | 0.89 (0.78–1.00) | <1e−4 | 71.1 | 0.93 (0.85–1.02) | <1e−4 | 84 |
Others | 26,391/31,489 | 0.91 (0.82–1.01) | <1e−4 | 70.3 | 1.03 (0.96–1.11) | <1e−4 | 57.2 | 1.00 (0.92–1.07) | <1e−4 | 64.8 | 0.89 (0.82–0.96) | <1e−4 | 66.5 | 0.96 (0.91–1.01) | <1e−4 | 70.7 |
ETHNICITIES | ||||||||||||||||
Asian | 33,039/38,092 | 0.86 (0.77–0.97) | <1e−4 | 76.4 | 1.0 (0.92–1.09) | <1e−4 | 68.3 | 0.96 (0.88–1.05) | <1e−4 | 74.1 | 0.87 (0.81–0.93) | <1e−4 | 68.2 | 0.93 (0.89–0.98) | <1e−4 | 76.4 |
Caucasian | 7273/9737 | 0.86 (0.63–1.18) | <1e−4 | 81.1 | 0.92 (0.75–1.13) | <1e−4 | 78.3 | 0.91 (0.72–1.15) | <1e−4 | 85.1 | 0.92 (0.73–1.15) | <1e−4 | 71.2 | 0.94 (0.78–1.13) | 0.00 | 86.5 |
Africans/mixed | 1361/1741 | 1.40 (0.89–2.21) | 0.058 | 53.1 | 1.27 (0.87–1.86) | 0.01 | 63.1 | 1.31 (0.95–1.80) | 0.02 | 60.5 | 1.24 (0.77–2.0) | 0.05 | 54.3 | 1.21 (0.99–1.49) | 0.047 | 55.3 |
CANCER CATEGORIES | ||||||||||||||||
GI | 16,537/21,226 | 0.87 (0.71–1.06) | <1e−4 | 83.7 | 0.96 (0.84–1.10) | <1e−4 | 76.8 | 0.93 (0.80–1.08) | <1e−4 | 82.9 | 0.90 (0.79–1.02) | <1e−4 | 76.1 | 0.94 (0.85–1.03) | <1e−4 | 85 |
HNC | 4,865/5,648 | 1.05 (0.76–1.46) | 0.001 | 68.9 | 1.10 (0.79–1.54) | <1e−4 | 75 | 1.08 (0.78–1.49) | <1e−4 | 76.2 | 0.99 (0.90–1.09) | 0.085 | 42.3 | 1.01 (0.85–1.21) | 5e−4 | 71.2 |
GyC | 1,394/1,573 | 0.85 (0.53–1.36) | 0.042 | 56.6 | 1.02 (0.66–1.58) | 0.061 | 52.5 | 0.96 (0.61–1.50) | 0.030 | 59.5 | 0.80 (0.68–0.95) | 0.346 | 10.8 | 0.88 (0.79–0.98) | 0.089 | 47.6 |
HM | 1,347/2,571 | 0.71 (0.34–1.49) | 1e−4 | 80.4 | 0.91 (0.77–1.09) | 0.071 | 50.7 | 0.79 (0.52–1.19) | 0.008 | 67.5 | 0.80 (0.42–1.51) | 0.00 | 80.2 | 0.83 (0.57–1.21) | 0.00 | 80.5 |
UG | 3,599/4,356 | 0.98 (0.74–1.30) | 0.002 | 61.5 | 1.19 (0.96–1.48) | 0.003 | 60.5 | 1.15 (0.94–1.42) | 0.002 | 61.3 | 0.91 (0.70–1.19) | 0.001 | 63.8 | 1.047 (0.91–1.19) | 0.002 | 61.5 |
Others | 13,710/16,018 | 0.86 (0.76–0.98) | <1e−4 | 57.2 | 0.98 (0.88–1.10) | <1e−4 | 56.7 | 0.95 (0.85–1.06) | <1e−4 | 62.4 | 0.87 (0.79–0.95) | 0.003 | 44.6 | 0.94 (0.87–1.00) | <1e−4 | 62.3 |
CANCER TYPES | ||||||||||||||||
BC e | 7,401/8,828 | 0.85 (0.71–1.01) | 0.001 | 56.4 | 0.93 (0.81–1.08) | 0.002 | 53.3 | 0.91 (0.78–1.06) | 2e−4 | 60.8 | 0.89 (0.79–1.01) | 0.024 | 43 | 0.93 (0.84–1.02) | <1e−4 | 62.7 |
HCCe | 5,401/6,326 | 0.73 (0.57–0.94) | <1e−4 | 69.5 | 0.92 (0.78–1.09) | 0.002 | 55.2 | 0.87 (0.73–1.04) | <1e−4 | 64.7 | 0.79 (0.66–0.95) | 2e−4 | 63.2 | 0.88 (0.78–0.98) | <1e−4 | 68.8 |
GC | 4,664/6,385 | 0.80 (0.47–1.36) | <1e−4 | 90.3 | 0.81 (0.56; 1.15) | <1e−4 | 88.6 | 0.80 (0.53–1.20) | <1e−4 | 92.1 | 0.91 (0.65–1.29) | <1e−4 | 81.5 | 0.88 (0.66–1.17) | <1e−4 | 92.4 |
CRCe | 2,567/4,211 | 1.21 (0.65–2.27) | <1e−4 | 87.6 | 1.12 (0.71–1.75) | <1e−4 | 81.1 | 1.13 (0.70–1.85) | <1e−4 | 84.7 | 1.08 (0.83–1.42) | <1e−4 | 78.6 | 1.06 (0.86–1.29) | <1e−4 | 86.4 |
LC e | 4,453/4,932 | 0.86 (0.63–1.17) | 0.009 | 60.2 | 1.01 (0.91–1.12) | 0.057 | 46.9 | 1.00 (0.82–1.21) | 0.015 | 57.7 | 0.82 (0.65–1.03) | 0.012 | 59 | 0.93 (0.81–1.08) | 0.004 | 64.5 |
BlC | 1,390/1,562 | 0.75 (0.41–1.39) | 0.060 | 59.3 | 1.01 (0.53–1.89) | 0.017 | 70.4 | 0.97 (0.62–1.52) | 0.088 | 54 | 0.77 (0.30–1.97) | 3e−4 | 84.3 | 0.94 (0.68–1.29) | 0.036 | 64.7 |
PC | 868/1,345 | 1.01 (0.74–1.39) | 0.396 | 1.8 | 1.27 (0.83–1.95) | 0.057 | 56.4 | 1.23 (0.83–1.83) | 0.069 | 54 | 0.94 (0.71–1.24) | 0.485 | 0 | 1.06 (0.93–1.22) | 0.241 | 27.1 |
OC | 2,138/2,957 | 0.98 (0.49–1.95) | <1e−4 | 81.6 | 1.14 (0.57–2.29) | <1e−4 | 82.3 | 1.07 (0.53–2.12) | <1e−4 | 85 | 0.87 (0.76–1.00) | 0.189 | 32.8 | 0.96 (0.66–1.40) | <1e−4 | 82 |
OvC | 843/1,100 | 0.81 (0.28–2.37) | 0.023 | 68.4 | 1.03 (0.38–2.78) | 0.029 | 66.6 | 0.95 (0.34–2.63) | 0.017 | 70.4 | 0.73 (0.60–0.90) | 0.332 | 12.1 | 0.88 (0.58–1.32) | 0.050 | 61.6 |
ESCC | 3,492/4,376 | 0.85 (0.49–1.47) | <1e−4 | 82.4 | 1.04 (0.83–1.31) | 0.039 | 57.2 | 0.99 (0.76; 1.29) | 0.008 | 67.8 | 0.81 (0.51–1.28) | <1e−4 | 81.3 | 0.94 (0.76–1.16) | 6e−4 | 76.8 |
Others | 8,214/11,444 | 0.98 (0.80–1.20) | <1e−4 | 68.5 | 1.05 (0.91–1.22) | <1e−4 | 61.5 | 1.03 (0.88–1.21) | <1e−4 | 68.3 | 0.96 (0.83–1.11) | <1e−4 | 61.7 | 1.00 (0.89–1.11) | <1e−4 | 72 |
The overall, HWD-sensitivity and subgroup analyses.
n represents number of cases and controls in each group.
Pooled ORs and 95% confidence intervals.
P-value of the heterogeneity test.
Meta-analysis of all studies excluding those with the control group not in HWE.
These subgroups were found to be influenced by departure from HWE. Please consult with the Supplementary Table S2 for details on HWD sensitivity and adjustments.
GI, cancers of digestive system; HNC, Head and neck carcinoma; GyC, Gynecologic cancers; HM, Hematological malignancies; UG, Urogenital cancers; BC, breast cancer; HCC, Hepatocellular cancer; GC, gastric cancer; CRC, colorectal cancer; LC, lung cancer; BlC, bladder cancer; PC, prostate cancer; OC, Oral cancer; OvC, ovarian cancer; ESCC, esophageal squamous cell carcinoma.
Significant associations are shown in boldface.